Gareth Morgan, MD, director of Myeloma Research at NYU Langone's Perlmutter Cancer Center, discusses where he sees the field headed for the treatment of patients with multiple myeloma.
While there are many treatment options available these patients are still relapsing, Morgan says. The treatments also have many side effects, so cellular therapy could replace many of the current therapies that are available.
Morgan says CAR T cells could lead to long-term survival at a limited cost from toxicity. More clinical trials are necessary to see where these drugs will benefit most.
For more resources and information regarding anticancer targeted therapies: [ Ссылка ]
